New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2013
07:41 EDTBIIBBiogen drops 7% after ALS drug misses endpoint in trial
Shares of Biogen Idec (BIIB) are down 7% in pre-market trading after the company said its Phase 3 trial investigating dexpramipexole in people with amyotrophic lateral sclerosis, or ALS, did not meet its primary endpoint. Biogen said it will discontinue development of dexpramipexole in ALS due to the trial results. Note earlier this morning, Piper Jaffray cut its rating on shares of Biogen to Neutral from Overweight. The stock is currently trading lower 7%, or $10.01, to $139.99 in pre-market trading.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
05:34 EDTBIIBSobi, Biogen announce approval of Elocta in Europe
Subscribe for More Information
November 20, 2015
07:17 EDTBIIBBiogen says Benepali receives 'positive' opinion from CHMP
Subscribe for More Information
November 10, 2015
07:03 EDTBIIBIsis Pharmaceuticals earns $2.8M milestone payment from Biogen
Isis Pharmaceuticals (ISIS) announced that it has earned a $2.8M milestone payment from Biogen (BIIB) related to the advancement of the ongoing Phase 1/2a study of ISIS-DMPK-2.5Rx in patients with myotonic dystrophy type I, or DM1. ISIS-DMPK-2.5Rx is designed to reduce the production of the toxic dystrophia myotonica-protein kinase RNA in cells, including muscle cells, for the potential treatment of DM1.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use